Amylyx (AMLX) downgraded to Buy after AMX0035 PSP halt; focus shifts to avexitide Phase 3 with Q3 2026 data and strong cash runway. Read the latest analysis on the stock here.

GLP-1 receptor agonists hold key market opportunities due to their effectiveness in diabetes and obesity management, ...

PORT SAINT LUCIE, FL, UNITED STATES, February 11, 2026 /EINPresswire.com/ -- Advancing Education, Awareness, and ...

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the U.S. Food and Drug Administration (FDA or the Agency) has ...

VTVT stock outlook: underfollowed T1D catalyst with Phase 3 CATT1 cadisegliatin data due 2H2026, improved timeline and runway ...

Mechanisms and Frontiers of Treatment for Diabetes-Related Epilepsy. Journal of Biosciences and Medicines, 14, 57-73. doi: 10.4236/jbm.2026.143006 . Diabetes mellitus (DM) is a metabolic disease ...

An innovative insulin implant could redefine the future of diabetes management. Here's how this breakthrough diabetes treatment works, its benefits, risks, and what it means for people living with ...

PDUFA action date set for August 23, 2026 If approved, DTX401 will be the first treatment to address the underlying cause of GDSIa NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmace ...

Beta Bionics, Inc. (NASDAQ:BBNX) Q4 2025 Earnings Call Transcript February 18, 2026 Operator: Good day, and thank you for standing by. Welcome to the Beta Bionics Inc. Q4 and Full Year 2025 Earnings ...

A type of diabetes first identified more than 70 years ago is now receiving a resurgence of attention as a result of a new name and an international working group.At the World Diabetes Congress in ...

Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound® (tirzepatide) to include the four-dose single-patient use KwikPen® that ...

Amylyx Pharmaceuticals (NASDAQ:AMLX) executives told investors the company entered 2026 with a focus on advancing avexitide ...